<SEC-DOCUMENT>0001013762-23-002966.txt : 20231011
<SEC-HEADER>0001013762-23-002966.hdr.sgml : 20231011
<ACCEPTANCE-DATETIME>20231011060957
ACCESSION NUMBER:		0001013762-23-002966
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		6
CONFORMED PERIOD OF REPORT:	20231011
FILED AS OF DATE:		20231011
DATE AS OF CHANGE:		20231011

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Immuron Ltd
		CENTRAL INDEX KEY:			0001660046
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38104
		FILM NUMBER:		231319376

	BUSINESS ADDRESS:	
		STREET 1:		62 LYGON STREET
		STREET 2:		LEVEL 3
		CITY:			CARLTON, VICTORIA
		STATE:			C3
		ZIP:			3053
		BUSINESS PHONE:		61 03 9824 5254

	MAIL ADDRESS:	
		STREET 1:		62 LYGON STREET
		STREET 2:		LEVEL 3
		CITY:			CARLTON, VICTORIA
		STATE:			C3
		ZIP:			3053
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea186599-6k_immuron.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Form 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 UNDER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">For the Month of October 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Commission File Number: 001-38104</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>IMMURON LIMITED</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Name of Registrant)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Level 3, 62 Lygon Street, Carlton South,
Victoria, 3053, Australia</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive office)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Form 20-F &#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form
40-F &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether by furnishing the information contained
in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Yes &#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
&#9746;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If &ldquo;Yes&rdquo; is marked, indicate below the file number assigned
to the registrant in connection with Rule 12g3-2(b): 82-</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>IMMURON LIMITED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>EXPLANATORY NOTE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Immuron Limited (the &ldquo;Company&rdquo;) published
one announcement (the &ldquo;Public Notices&rdquo;) to the Australian Securities Exchange on October 11, 2023 titled:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Immuron
achieves record quarterly Travelan sales&rdquo;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A copy of the Public Notice is attached as an exhibit to this report
on Form 6-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This report on Form 6-K (including the exhibit
hereto) shall not be deemed to be &ldquo;filed&rdquo; for purposes of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange
Act&rdquo;) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be
expressly set forth by specific reference in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>EXHIBITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: bottom; width: 9%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit</B> <BR>
<B>Number</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 90%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="ea186599ex99-1_immuron.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immuron achieves record quarterly Travelan sales</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IMMURON LIMITED</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 36%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left"><IMG SRC="image_001.jpg" ALT=""></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: October 11, 2023</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Phillip Hains</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phillip Hains</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Secretary</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea186599ex99-1_immuron.htm
<DESCRIPTION>IMMURON ACHIEVES RECORD QUARTERLY TRAVELAN SALES
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex99-1_001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Immuron achieves record quarterly Travelan<SUP>&reg;
</SUP>sales</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Highlights:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Record
                                            quarterly Travelan<SUP>&reg;</SUP> sales of $1,550,240</B></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Total sales of A$1,565,767 in Q1, FY24</B></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">o</TD><TD><B>$1,508,933 increase on Q1, FY23 sales</B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">o</TD><TD><B>130% higher than pre-pandemic period Q1, FY20 sales</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Melbourne, Australia, October 11, 2023: Immuron
Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce record
quarterly sales (unaudited net sales) of its over-the-counter gastrointestinal and digestive health immune supplement Travelan<SUP>&reg;</SUP>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Australia</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Immuron previously reported (August 9, 2023)
that short term stock outages of Travelan<SUP>&reg;</SUP> in some wholesalers and pharmacies in the June 2023 quarter was resolved following
receipt of GMP Clearance from the Therapeutic Goods Administration (TGA). Immuron has since supplied product to wholesalers who in turn
have supplied retail pharmacies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sales of Travelan<SUP>&reg;</SUP> increased to
AUD $1,339,160 in Q1, FY24, compared to AUD $25,565 in Q1, FY23. Sales increased by $940,991 (236%) on the pre-pandemic peak period (Q1,
FY20).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This increase partially reflects 3 months (May,
June, July) of backorders accrued while awaiting GMP Clearance from the TGA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Immuron anticipates continued demand for replenishment
of Travelan<SUP>&reg;</SUP> as retail pharmacies sell to consumers. Australian Bureau of Statistics: short term resident returns in July
2023 were 48% higher than July 2022 and approaching pre-pandemic levels (89% of July 2019)<SUP>1</SUP>. Cumulative short term resident
returns in the 12 months to July 2023 were 77% of those in the pre-pandemic period 12 months to July 2019. <SUP>1</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>USA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sales of Travelan<SUP>&reg;</SUP> increased to
AUD $211,080 in Q1, FY24, compared to AUD $16,614 in Q1, FY23. Sales were lower by $20,499 (-9%) on the pre-pandemic peak period (Q1,
FY20).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">International Trade Administration Total U.S. citizen international
visitor departures from the United States in June 2023 increased 20.2% compared to June 2022 and were 99.4% of total departures in June
2019. <SUP>2</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="ex99-1_002.jpg" ALT="">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="border-bottom: Black 1.5pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="ex99-1_003.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Immuron&rsquo;s target departure markets <SUP>3</SUP>, June 2023 quarter
departures were only 3% lower than the pre-pandemic period June 2019. <SUP>2</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Immuron previously reported (July 5, 2023) that it had shipped inventory
to Amazon for launch in USA. The Amazon launch has been progressing well with sales ahead of budget. We are now entering the low travel
season in USA. Immuron anticipates sales to grow strongly closer to the peak spring / summer travel period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">https://www.abs.gov.au/statistics/industry/tourism-and-transport/overseas-arrivals-and-departures-australia/latest-release</TD>
</TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">https://www.trade.gov/sites/default/files/2023-09/US-Outbound-to-World-Regions.xlsx</TD>
</TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">Caribbean, Asia, South America, Central America, Africa, Mexico</TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This release has been authorised by the directors of Immuron Limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">- - - END - - -</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>COMPANY CONTACT:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Steven Lydeamore</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ph: +61 (0)3 9824 5254</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">info@immuron.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Travelan<SUP>&reg;</SUP></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">Travelan<SUP>&reg;
</SUP>is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting travelers&rsquo; diarrhea,
<FONT STYLE="background-color: white">a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce</FONT>.
Travelan<SUP>&reg;</SUP> is a highly purified tabletized preparation of hyper immune bovine antibodies and other factors, which when
taken with meals bind to diarrhea-causing bacteria and prevent colonization and the pathology associated with travelers&rsquo; diarrhea.
In Australia, Travelan<SUP>&reg;</SUP> is a listed medicine on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated
to reduce the risk of Travelers&rsquo; Diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada,
Travelan<SUP>&reg;</SUP> is a licensed natural health product (NPN 80046016) and is indicated to reduce the risk of Travelers&rsquo;
Diarrhea. In the U.S., Travelan<SUP>&reg;</SUP> is sold as a dietary supplement for digestive tract protection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>About Travelers&rsquo; diarrhea</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">Travelers&rsquo; diarrhea
is a gastrointestinal infection with symptoms that include loose, watery (and occasionally bloody) stools, abdominal cramping, bloating,
and fever, Enteropathogenic bacteria are responsible for most cases, with enterotoxigenic <I>Escherichia coli</I> (ETEC) playing a dominant
causative role. Campylobacter spp. are also responsible for a significant proportion of cases. The more serious infections with Salmonella
spp. the bacillary dysentery organisms belonging to Shigella spp. and Vibrio spp. (the causative agent of cholera) are often confused
with travelers&rsquo; diarrhea as they may be contracted while travelling and initial symptoms are often indistinguishable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><IMG SRC="ex99-1_002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="border-bottom: Black 1.5pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="ex99-1_003.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><B>About Immuron</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">Immuron Limited (ASX:
IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal
antibodies for the treatment of inflammatory mediated and infectious diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">For more information
visit: http://www.immuron.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>FORWARD-LOOKING STATEMENTS:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release may contain &ldquo;forward-looking
statements&rdquo; within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934,
each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development
programs and any other statements that are not historical facts. Forward-looking statements are based on management&rsquo;s current expectations
and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock
value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth
strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the
results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties
relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key
personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and
intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation
or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change
in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by
law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><IMG SRC="ex99-1_002.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">3</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !$ #H# 2(  A$! Q$!_\0
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MJM%<(UY-;EAYB -C_9/3]<U9/3BL+5[AM-U+3[TJ/(>3[+._=0WW#_WUQ^-
M&]134/6G4 %%%% !1110 50U73X=4TNXL)]PCGC*%EZKZ$>X."/I5^FN-PQQ
M^- &)X9U*:]TPPWF!?V;FVNE_P!M?XOHRX8?6M:6XBB*>9(J;V"+N.,L>P]Z
MY?6C_P (]XFM==7Y;*\VV>H<\*<_NI3]"=I/HPJ3Q1=*NI^&K4C+7&J*0/\
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GVTA"C. &.3^M '5BB@44 %%%% !1110 4F!Z444  X7BEHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !* 0P# 2(  A$! Q$!_\0
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MH/Q7F\]8=;@0QL<>?",%?JO?\*V?$_Q+LM*(M]+5+VX*@F3=^[3(XZ=36?\
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MI[9:3FXL8+@@ R1JY [9&:\[T[XG32^(197\%M!:!W#S9.5"@G^@KO\ 2_\
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M*OOJG_H0KC/A!_R%M2_ZX+_Z%7:?$/\ Y$F^_P" ?^A"N+^$'_(4U+_K@O\
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M4H-6TNWOK=@T<R!N.Q[CZ@TL8KTZ<EM;_(,([5*D7O?_ #+E>&?$S_D=Y_\
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98Y&&&D8EG/XFM:BBLY2<G=LTC%15DC__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>ex99-1_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !4 S$# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJ
M&>\MK89GN(HA_MN%_G65<^+=%MNMX)#Z1J6_7I6D*52?PQ;^1E.M3I_')+YF
MW17'7/Q"LDR+>SFD/8NP4?IFLBY^(&HR<00P0CZ%C^O'Z5V0R[$2^S;U.&>:
M86'VK^B/2*CFN(+==TTT<:^KL!_.O)+GQ-K%UD27\H![(=G\L5F/-)(Q9W9F
M/4D\UUPRB7VY?<<53.X_8A][/6;GQ7HUMUO%D/I&"WZCBL>Y^(-HF1;6<LA[
M&1@O\LUYWFC-=L,KH1WN_P"O(X*F<8F7PV7R_P SK+GQYJ<N1"D, [$+D_KG
M^58]SKVJ7?\ KKZ<@]@V!^0XK+S37ECC&7=5^IQ79##48?#%'!4Q5>I\<V_F
M3^:_]XT53^WVO_/Q'^=%;Z&&I[Y114=Q/':VTMQ,VV*)"[GT &37PA^BE'6M
M=T_P_9&ZU"<1J>%4<LY] *\YOOC#+YI%AID8C!ZS.22/H,8J=)-/O()?&GBD
M>; [E-/LCR-H)Q\O<G!]NI-00_$'4]1#1VGARR;3@<"*3H1Z9Z?I77"FME&[
M%I:\G8MZ3\7K>:9(M4L#"K'!EA;('_ 3_C7H]I=V]_:QW5K,DT$@RCJ<@BO#
M/$>F:7J-C_;>BPFTVRB&]LF_Y8.>A'^R<8]/I5WX;>(YM(UT:1<LPMKI]FUO
MX).Q'UZ?_JISI*4;Q5F-JVJ9[9117"_%#4[_ $O1K.2PO)K:1IB&:)L$C'2N
M>E3=2:@NIG4FJ<7)]#NJ*YV/6_[+\!P:O=LTSI:(Y+'EW(&,GW)KS_3;;QCX
MZ\W4%U0VMLKE4^=D3/HH7T]36U/#.2<I-)+2YG.NHV25VSV*BO&+CQ7XL\)R
M7.C7TPGG*CR9I/G*@]U/?Z'I5UO"GCLV?]J'6)/M6WS/(\]M_KCTS[5H\'RZ
MRFDGMYF:Q5](Q;:W\CUJBN(^'OBZY\06\]EJ&#>6P!\P#&]3QR/4&LKQGXJU
M>Y\1)X;T!VCER$DD3AF8C. >P ZFLUA9NHZ;Z?=8T>(A[-374],HKR*^T;QK
MX2M?[676#<1QD-,@D9P![ANH^E,MK_Q;\0;R465V+"TA #A'*H#]1R36GU.Z
MYE-<O<S^M6?*XN_8]@HKQ\:OXE\ ZW!;:K=->V,O/+%@RYP2I/((]*ZWXCZG
M=V/A2*ZTZ[EMW>=,21-@E2":AX62G&*::ELRUB$XR;5FMT=G16)X0N9[SPGI
MMQ<RO+-)%EW<Y+')ZUD?$O4+S3?#*3V-U+;2FX5=\38.,'BLHTG*K[/K>QI*
MHE3]IY7.RHK@=2U34(OA/!J"7DRWABC)G#?.26YYKE=(N?&7C&V2RM-0DBM[
M88EN&<KO8G/S$<D^PK:&$<HN3DDD[&4L2DU%)MM7/:**\AUCQ!XF%U:> O#,
MHFU:&(&^U#)(B!YX)Z<$<]>@%4;[P2FALDNK_$;4(=5;YLQEF"GUVYSC\JE8
M:[M??;1OYF[G&,>:;MZGME%>?^%/$>LZ??)HGB25+[SH3/I^IVZ\748Z@C^\
M!SCK7=QW,,ML+F.56A*[@X/&*PG3<'9E71+17D=UXB\2>-];EL- E:ULH\_,
MK;?ESC<S=>?04S4--\:^#(AJ*ZJUW;(1YF'9U'^\K=O>NM8-Z1E)*3Z'*\4M
M6HMI=3U^BL7PMX@C\2:)%?(GER9*2QY^ZXZ_A6U7'*+C)Q>Z.F,E))H****D
MH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;\1>'M"\--]J739#<23HIVQ1JC+C<>I8L*T(;LQ3>,M,B/[F"-IHP.B%XR6
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1T4#'%W/5F/XTVBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** /J*BO%?^%J^(?[EE_P!^C_\ %4X?
M%?7QUAL3_P!LF_\ BJ^9_LO$>7WGUG]KX;S^X]HHKQD?%C7O^?>Q_P"_;?\
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M^3^]^E1T4 /\Z3^\:3S'_OG\Z;10 NYC_$?SI,GU-%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
A44 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ex99-1_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  R +<# 2(  A$! Q$!_\0
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4H **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
